U ntil recent years, critical care clinicians considered the ICU the limit of their clinical and academic domain and survival to discharge from hospital the key measure of success. We now know this is just the start of the recovery journey for many patients. Survivors suffer from an array of physical, psychological, and cognitive impairments and disabilities that for many represent a step change deterioration from their preillness status (1, 2) . Recovery is variable, often incomplete, and can take many months or years (3, 4) . The impact on function is often greatest in those who had best preadmission health (5) . The critical care community has coined the term "post intensive care syndrome" for this array of sequelae (1) . Perhaps, the most useful function of this term is to raise awareness within the speciality that critical illness survival does not guarantee health, and that improving survivorship is part of our remit. In fact, improving survivorship is becoming one of the great challenges for critical care as more patients, often with significant comorbidity, are successfully treated in ICUs (6) . If critical care professionals do not drive this agenda, who else will?
Fatigue and weakness are the most prevalent physical symptoms after critical illness. We know that weakness results from both acute myopathy and neuropathy (7) . Our understanding of the underlying mechanisms is increasing, but is far from complete. Muscle injury, in particular, is initiated early in critical illness, probably within the first few hours, and is likely mediated by a range of inflammatory mechanisms (8) . These result in muscle loss and atrophy, which is easy to see in the chronically critically ill patient; however, disordered muscle contractile function is also likely (7) .
Potential therapeutic approaches to minimize muscle injury during critical illness or to promote its recovery can broadly be categorized as those that modify the injurious process and those that increase muscle structure and function. Recent research has focused heavily on the effectiveness of mobilization and exercise at different stages of recovery. Current evidence supports strategies that promote early mobilization during ICU care (9) ; in contrast, physical rehabilitation started after ICU or hospital discharge has not been effective (10, 11) .
It seems logical to seek pharmacological interventions that may attenuate muscle injury or help recovery of structure and function. In this issue of Critical Care Medicine, Shepherd et al (12) report a systematic review of published studies of the impact of pharmacological therapies for the prevention and treatment of muscle weakness after critical illness. Their search terms found more than 13,000 articles, but after screening only 10 randomized or quasirandomized intervention studies were identified that reported effects on a measure of physical function, muscle strength, muscle bulk, or physical mobility. These studies evaluated a diverse range of interventions. These included therapies with plausibility to modify inflammation (immunoglobulin) or attenuate muscle loss associated with high metabolic rate (propranolol). For the majority, the intervention had greatest plausibility for increasing muscle mass, namely, anabolic steroid (oxandrolone), growth hormone, glutamine, or insulin/glycemic control. Glycemic control may also decrease critical illness polyneuropathy. The authors undertook an assessment of study quality using the Cochrane risk of bias tool. All but one study (a report of two randomized controlled trials of growth hormone therapy) (13) enrolled less than 50 subjects, study quality was low, and the populations were diverse. The outcomes measured were also highly variable, including a range of measures of protein turnover, muscle structure and composition, and function. Not surprisingly, it was not feasible or appropriate to calculate summary measures of effectiveness, and the authors concluded that none of these interventions can be recommended based on current evidence.
The current interest in research to improve physical recovery following critical illness makes this systematic review timely and useful. It clearly shows that we need more high-quality research. More importantly, it raises important methodological issues that need to be addressed in future studies. First, populations need to be clearly defined. Characteristics include not only the type of acute disease but also factors such as preexisting comorbidities and age all of which may influence the recovery potential and response to interventions. Second, timing is likely to be critical. This might include the degree of ongoing systemic inflammation, organ failure, or other biomarkers that indicate the potential for anabolism and/or the pharmacokinetics and pharmacodynamics of drug therapies. It seems highly plausible that pharmacologic interventions may have differing effects at different stages of critical illness, potentially including both benefit and harm. Finally, the outcome measures chosen must be shown to have potential clinical relevance and assess the risk to benefit balance of the therapy. Virtually all the studies included used physiological measures of muscle or nerve function. The only larger study, which reported the concordant results of two parallel trials of growth hormone therapy in mixed critically ill populations, found a doubling of the risk of death with this therapy despite the strong biological plausibility for decreasing ICU-acquired weakness (13) .
There is much to learn about ICU-acquired weakness. Pharmacological therapies will need strong preclinical biological rationale and early phase evidence of safety before large numbers of critically ill patients are included in efficacy trials. Without robust early data, there is a high risk of undertaking "negative" trials or worse exposing patients to a therapy that might cause harm. This research area is still in its infancy, and it is worth reflecting that cancer cachexia has been studied for far longer, but remains incompletely understood and without pharmacologic interventions with proven effectiveness (14) . pneumonia. Using propensity score-matched case-control analysis, they showed that the median viral shedding time was longer among patients receiving high-dose corticosteroids. More importantly, patients receiving corticosteroids also had a significantly greater risk of mortality. This same group of investigators showed that the use of corticosteroids was common among patients hospitalized with this form of influenza with 62.2% of patients receiving at least one glucocorticoid (2) . Despite the use of corticosteroids, progression to Acute Respiratory Distress Syndrome (ARDS) was high (71.2%) as was mortality (≈ 30%). This experience would suggest that adjuvant corticosteroids should not be routinely used among patients with severe influenza to include patients developing respiratory failure and ARDS. A potential explanation for this is the impact of corticosteroids on the host immune response allowing the viral infection to be unchecked accounting for the prolonged viral shedding and potentially for the greater mortality. It must be recognized that this study is limited by the retrospective nature of the analysis and being performed in a single country experiencing an outbreak with a specific strain of influenza. In addition, the propensity score methodology lowered the number of patients receiving high-dose corticosteroids to 26 potentially limiting the overall power of the analysis to identify
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